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Background. Elevated levels of circulating interleukin-6 (IL-6) have been reported in patients with abdominal aortic
aneurysms (AAAs). Although this implicates inflammation as a cause of AAAs, there is also evidence that the aneurysmal
aorta may secrete IL-6 into the circulation as a result of aortic proteolysis. Genetic association studies are one means of
trying to clarify the role of specific mediators in the causal pathway. The aim of the present study was to examine the as-
sociation between variants of the IL-6 gene and AAAs.
Methods. An association study involving 677 men with screen-detected AAAs and 656 age-matched controls was per-
formed. Three variants in the IL-6 promoter region were analysed: IL-6-174G> C (rs1800795), IL-6-572G>C
(rs1800796) and IL-6-597G>A (rs1800797). Univariate regression of SNP genotype on AAA as a binary outcome
was initially performed under a range of genetic models (additive, dominant and recessive). This was followed by multi-
variate analyses, testing the same models but including risk factors known to be associated with AAAs. All analyses and
haplotype estimation were performed under a generalized linear model framework.
Results. IL-6-572G>C polymorphism (frequency 1.5% in cases) was identified as an independent risk factor for AAA
with an odds ratio (OR) of 6.00 (95%CI: 1.22, 29.41) when applied to the recessive model. No association was seen in
the additive or dominant models. In a multivariate analysis using the most common haplotype (h.111, frequency
48.7%) as a reference, h.211 (frequency 4.4%) was an independent risk factor for AAA (OR 1.56, 95%CI: 1.02, 2.39).
Conclusion. The IL-6 572G>C polymorphism (and h.211 haplotype) is associated with AAA, however it is too rare to be
an important cause of most AAAs. This does not support the concept that the elevated level of IL-6 reported in patients with
AAAs is a primary cause of the aneurysmal process.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Inflammation plays a fundamental role in the patho-
genesis of abdominal aortic aneurysms (AAAs). His-
tological examination of aortic wall from AAAs has
identified extensive inflammatory infiltrates with
macrophages, monocytes, plasma cells and CD3þ T
lymphocytes that express CD4 and CD8 predominat-
ing.1 Cytokines, as mediators of inflammation and
regulators of matrix metalloproteinases (MMPs),
may be important in the pathogenesis of AAA.2,3
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that has been implicated in various manifestations of
cardiovascular disease, particularly coronary heart
disease.4 Elevated levels of circulating IL-6 have been
reported in patients with AAA and levels appear to
correlate with aortic diameter.2,5,6 There is some evi-
dence that AAAs may actually secrete IL-6 into the
circulation.6,7 It is unclear whether the inflammation
seen in the walls of AAAs is causing the aneurysmal
dilatation or is secondary to proteolysis with elastin
degradation products serving as chemotactic agents.8
Genetic association studies are one means of trying to
clarify the role of specific mediators in a causal path-
way. Circulating levels of IL-6 may be influenced by
common genetic variants of the IL-6 gene promoter.9,10
The aim of the present study was to examine then behalf of European Society for Vascular Surgery.
32 L. Smallwood et al.association between polymorphisms and haplotypes
of the IL-6 gene promoter and AAAs in a large well-
characterised case control study.
Methods
Subject recruitment
Details of the Western Australian trial of screening for
AAAs are described elsewhere.11,12 Between 1996 and
1998, eligible men were identified and recruited from
the electoral roll, and invited to attend a screening
clinic close to their home. On arrival at the clinic,
the trial was explained to each participant and written
consent was obtained. A risk factor questionnaire cov-
ering aspects of medical history and lifestyle relevant
to CVD was completed. Height, weight, girth at hips
and waist, and blood pressure were measured. The
maximum diameter of the infra-renal aorta was then
measured using a Toshiba Capasee ultrasound ma-
chine with a 3.75 MHz probe (Toshiba Australia,
North Ryde, NSW). All staff performing ultrasound
measurements participated in regular quality control
exercises in which inter- and intra-rater agreement
was examined by taking paired, blinded measure-
ments of aortic diameters in series of ten men. This re-
vealed that 95% of differences were less than 3 mm.
Between 1996 and 1998, 12,203 men age 65e83
years attended for baseline screening and 875 with
AAAs (aortic diameters 30 mm) were identified.
Men with large AAAs (generally >50 mm) were re-
ferred for surgical assessment and were not actively
recruited into surveillance and follow-up. All men
with small AAAs (aortic diameter 30e50 mm) were
invited to attend a follow-up study (1997e2004) in-
volving repeat ultrasound scans at intervals of 6e12
months.13 At the first follow-up visit, a sample of ve-
nous blood was obtained from all consenting men.
Men without AAAs were also reviewed as part of
a separate study in 2001e4 which also included ve-
nous blood sampling.14 The controls for the present
study consisted of randomly selected men with aortic
diameters in a previously defined reference range of
19e22 mm.15
DNA extraction and genotyping
Genomic DNA was extracted from EDTA anti-
coagulated whole blood using a standard Triton
X-100 procedure. The DNA was resuspended in
TE buffer and quantified using either ultraviolet spec-
trophotometric methods or NanoDrop ND-1000
(NanoDrop Technologies). Three single nucleotideEur J Vasc Endovasc Surg Vol 35, January 2008polymoprhisms (SNPs) in the IL-6 promoter region
were analysed. IL-6-174G>C (rs1800795) genotypes
were determined using fluorescent Polymerase Chain
Reaction (PCR) Single Stranded Conformational Poly-
morphism (SSCP) analysis whilst IL-6-572G>C
(rs1800796) and IL-6-597G>A (rs1800797) genotypes
were determined using fluorescent Taqman probes.
For SSCP analysis, the use of fluorescent labelled
primers with the initial PCR enabled rapid genotype
identification using a Gel-Scan 2000 real-time DNA
fragment analyser (Corbett Research, Sydney). The
primer sequences (5’-AGGAAGAGTGGTTCTGCTTC-
3’ and 5’-CTTTGTT-GGAGGGTGAGGGTG-3’) were
designed to incorporate the IL-6-174G>C SNP and
produce a PCR product of 165 base pairs in size. Both
the forward and reverse primers were labelled at the
5’ end with HEX fluorescent dye (Geneworks,
Adelaide). All reactions were set up using a bulk ampli-
fication mixture to improve comparability between
samples. PCR reactions were performed in a final
volume of 15 ml with 1 mL template used with a total
of 50 ng of genomic DNA. The PCR cycling comprised
a 10 minute denaturation step followed by 32 cycles of:
94C for 30 seconds, 64C for 30 seconds and 72C for 30
seconds. After cycling, a final extension phase of 7 min-
utes at 72C was performed. The HEX-labelled PCR
product was analysed for the IL-6-174G>C SNP using
fluorescent single strand conformation polymorphism
as previously described.16
For Taqman analysis, custom assays
(C__11326893_10 and C__1839695_20) were synthes-
ised by Applied Biosystems (USA). 10 ng of DNA
was amplified in a volume of 5 ml using a MJ research
PTC e 200 Peltier Thermocycler with a 384 well block,
under the following conditions; 95C for 10 min, fol-
lowed by 40 cycles of 92C for 15 sec and 60C for
1 min. The Pplates were then spun briefly at 1500 rpm
using a Quantum Scientific 2e5 Sigma Plate Spinner,
and fluorescence was read using a Perkin Elmer Life
Science Wallac VICTOR2 1420 Multi-label Counter.
Genotypes were assigned from the clustered samples.
Levels of circulating IL-6 concentration were not
available, however levels of C-reactive protein were
measured in a sub-group of men (n¼ 974) by
a high-sensitivity assay using the particle enhanced
immunonephelometry system on the BNII analyzer
(Dade Behring, Marburg, Germany).
Statistical methods
All loci were tested for deviations from Hardy-
Weinberg equilibrium by means of a standard chi-
squared test and significant deviations ( p< 0.05) were
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regression of SNP genotype on AAA as a binary out-
come was initially performed under a range of genetic
models (additive, dominant and recessive). This was
followed by multivariate analyses, with independent
variables selected via step-wise regression based on
prior evidence of their involvement in AAA develop-
ment. The three IL-6 polymorphisms were then
sequentially added to this model.
Haplotypes were inferred using the EM algorithm17
and a global test of haplotype association was initially
performed taking the most common haplotype as
baseline and comparing all other haplotypes simulta-
neously. Any haplotypes that showed statistical signif-
icance in this analysis were then explored individually.
All analyses and haplotype estimationswere performed
under a generalized linear model framework18 as
implemented in the software package SimHap.19
Results
Of 875 men with AAAs (30 mm) at baseline, 677
(77%) attended for follow-up and agreed to DNA test-
ing. This represents 82% (652/791) of men with small
AAAs (30e49 mm) and 30% of men with larger AAAs
(50 mm). The baseline characteristics of 677 cases of
AAA and 656 controls are shown in Table 1. Amongst
Table 1. Baseline characteristics of the AAA cases and the con-
trols. Age, BMI, BP and aortic diameter are all expressed as means
(1SD). Remaining variables as percentage (number)
Cases
(n¼ 677)
Controls
(n¼ 656)
Age (years) 73.3 (4.4) 72.3 (3.9)
BMI (kg/m2) 27.2 (3.7) 26.6 (3.2)
Systolic BP (mmHg) 157.3 (21.9) 155.0 (19.5)
Diastolic BP (mmHg) 90.9 (12.1) 90.0 (11.0)
Aortic diameter (mm) 35.7 (6.8) 21.1 (1.1)
Waist Hip Ratio
<1.00 66.2 (448) 75.9 (498)
1.00 33.8 (229) 24.1 (158)
Place of Birth
Australia 57.6 (390) 63.6 (417)
Northern Europe 29.2 (198) 26.4 (173)
Mediterranean 6.1 (41) 4.4 (29)
Other 7.1 (48) 5.8 (38)
History of stroke 10.9 (74) 4.7 (31)
History of myocardial infarction 26.1 (177) 8.5 (56)
History of coronary artery surgery 15.8 (107) 5.8 (38)
History of diabetes 9.9 (67) 5.8 (38)
Father had AAA 1.8 (12) 1.1 (7)
Treatment for hypertension 46.4 (314) 28.4 (186)
Smoking Status
Never smoked 14.5 (98) 36.0 (236)
Ex-smoker 67.8 (459) 54.7 (359)
Current smoker <25/day 14.2 (96) 7.9 (52)
Current smoker 25/day 3.5 (24) 1.4 (9)
Vigorous exercise 20.1 (136) 31.4 (206)
Non-vigorous exercise 63.5 (430) 70.6 (463)men with AAAs there were 534 with aortic diameters
in the range 30e39 mm, 118 in the range 40e49 mm
and 25 in the range 50þmm. Genotyping was
successful in the following percentages of cases and
controls respectively: IL-6-174G>C (91.6%, 98.2%),
IL-6-572G>C (97.5%, 99.7%) and IL-6-597G>A
(98.1%, 99.1%). Genotype distributions of the control
subjects were in Hardy-Weinberg equilibrium for all
polymorphisms. The frequencies of rare alleles for
all IL-6 variants and haplotypes in both cases and
controls were similar to those reported in white pop-
ulations.10,20,21 No statistically significant differences
were found between cases and controls with respect
to the rare allele or genotype frequencies of any
SNPs (Table 2).
The IL-6-174G>C and IL-6-597G>A polymor-
phisms were not identified as independent risk factors
for AAA in any multivariate models (data not shown).
The rare IL-6-572G>C polymorphism was identified
as an independent risk factor for AAA (Table 3) with
an odds ratio (OR) of 5.78 (95%CI:1.18, 28.42) when ap-
plied to the recessive model. No association was seen
in the additive or dominant models. In a sub-group
analysis (data not shown), there were no significant as-
sociations between any genotypes and larger AAAs
(aortic diameter 40 mm, n¼ 143). The -572CC geno-
type has a frequency of 1.5% amongst men with
AAAs. The geometric mean CRP levels (mg/L) were:
2.23 (572GG, n¼ 864), 2.05 (572GC, n¼ 102) and 1.00
(572CC, n¼ 8).
Table 4 shows the frequencies of various IL-6 hap-
lotypes. In a multivariate analysis incorporating all
haplotypes, and using the most common haplotype
(h.111) as a reference, h.211 was an independent risk
factor for AAA (OR 1.55, 95%CI: 1.01, 2.37). This hap-
lotype had a frequency of 4.4% and the association
with AAA was only marginally significant with
a p-value of 0.04. It was not apparent from the individ-
ual analysis of the IL-6 h.211 haplotype whether the
mode of inheritance of this haplotype is additive,
dominant or recessive.
Table 2. Distribution of IL-6 genotypes
SNP n (%) p Value*
174G>C GG GC CC 0.53
Cases 222 (35.5) 300 (47.9) 104 (16.6)
Controls 224 (34.5) 302 (46.5) 124 (19.0)
572G>C GG GC CC 0.13
Cases 587 (88.8) 64 (9.7) 10 (1.5)
Controls 582 (88.9) 70 (10.7) 3 (0.5)
597G>A GG GA AA 0.96
Cases 245 (36.8) 312 (46.9) 108 (16.2)
Controls 236 (36.3) 306 (47.0) 109 (16.7)
*Cases vs controls.
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The present study examined the association between
three polymorphisms of the IL-6 gene (-174G>C, -
572G>C and -597G>A) and AAA. These polymor-
phisms were chosen on the basis of evidence that
they may be of functional significance.10 In particular
IL-6e174G>C and IL-6-572G>C have been shown
to predict plasma IL-6 levels after coronary artery sur-
gery and could therefore be potentially pro-inflamma-
tory.20 A positive association between the -572 CC
genotype (and a haplotype including this variant)
and AAA was observed in the present study.
The strengths of the study include its large size
(n¼ 1,333) and the fact that all control subjects had ul-
trasound scans to ensure that they did not have an
AAA. In addition, the inclusion of three polymorphisms
allowed haplotype analyses. Measurement of gene
products (intermediate phenotypes) helps provide
a causal link between genotype and clinical phenotype.
Although plasma IL-6 concentrations were not avail-
able, CRP concentrations were available in a proportion
of men as a measure of intermediate phenotype.
Table 3. Results of the multivariate modelling including IL-6-
572G>C variant
Variable OR (95% CI) p Value
Age (yrs) 1.08 (1.04, 1.11) <0.001
Diastolic BP (mmHg) 1.01 (1.00, 1.03) 0.02
History of stroke 2.00 (1.18, 3.37) 0.01
History of myocardial infarction 2.93 (1.97, 4.36) <0.001
History coronary artery surgery 2.35 (1.49, 3.69) <0.001
Treatment for hypertension 1.58 (1.21, 2.07) <0.001
Smoking status
Never e e
Ex-smoker 3.23 (2.34, 4.47) <0.001
Current smoker <25/day 5.86 (3.55, 9.69) <0.001
Current smoker 25/day 6.33 (2.65, 15.16) <0.001
Obesity (Waist Hip Ratio  1.00) 1.55 (1.16, 2.07) 0.002
Vigorous exercise 0.56 (0.41, 0.76) <0.001
IL-6-572 CC genotype 5.78 (1.18, 28.42) 0.031
Table 4. IL-6 haplotypes and their association with AAA in mul-
tivariate modelling. All haplotypes with frequencies <1% were
grouped together in the Rare category
174G>C 597G>A 572G>C Frequency OR (95%CI)
h.111 G G G 0.487 e
h.221 C A G 0.388 0.96
(0.79, 1.17)
h.112 G G C 0.057 1.14
(0.78, 1.68)
h.211 C G G 0.044 1.55
(1.01, 2.37)
Rare - - - 0.024 1.97
(1.05, 3.65)Eur J Vasc Endovasc Surg Vol 35, January 2008Theusefulness of inflammatorymarkers, particularly
IL-6 and CRP, in cardiovascular disease has attracted
considerable interest e and debate - over the last de-
cade.4 IL-6 is an inflammatory cytokine that induces
the synthesis of CRP and other acute phase proteins.22
CRP may also be produced in situ in the arterial wall.23
Circulating levels of IL-6 andCRP in response to inflam-
matory stimuli appear to be under genetic control.20,24,25
This has lead to a search for associationsbetweengenetic
variants and various manifestations of cardiovascular
disease.
The IL-6 polymorphism that has been most studied
in cardiovascular disease is IL-6 e174G>C.6,20,21 Al-
though the -174CC genotype appears to be associated
with the greatest risk of cardiovascular disease, there
are conflicting reports about its influence on levels of
circulating IL-6 and CRP.6,21,25 No association was
detected between the e174G>C genotype and AAA
in the present study. This is in agreement with the
only previous study to assess this variant in AAA.26
It is also relevant to note that a recent meta-analysis
did not show a significant association between the e
174G>C genotype and coronary heart disease.21
Histological and molecular evidence of inflamma-
tion is always found in the walls of aneurysmal aor-
tas.27 However, the role of inflammation in the
causal pathway of AAAs remains to be established.
Several studies have demonstrated that circulating
markers of inflammation are elevated in the presence
of an AAA.2,28 Levels of CRP are higher in patients
with AAAs and appear to increase with aneurysm
diameter.13,23,29 Levels of IL-6 also rise with increasing
aortic diameter.5,6
Despite these observations, the possibility that the
aortic wall inflammation and the changes seen in the
circulating cytokine profile of patients with AAAs
are secondary responses to the structural failure of
the aortic wall needs to be considered. Baseline levels
of CRP and IL-6 do not predict rates of expansion of
AAAs.6,13 Jones et al. suggested that the increased
levels of IL-6 seen in patients with AAAs were due
to the presence of the AAA itself after finding levels
of IL-6 were higher in the iliac than the brachial ar-
teries.6 This observation has been replicated for both
thoracic and abdominal aortic aneurysms, with a gra-
dient of increasing IL-6 levels as more distal aortic
blood sampling.7 To date, all association studies
have failed to identify a convincing association be-
tween AAA and common functional variants of genes
for a range of inflammatory mediators (including
TNFa, IL-1 and IL-6).26,30 In the present study, the
only genotype found to be an independent risk factor
for AAAwas IL-6-572 CC. Although there is evidence
that levels of IL-6 are greater in carriers of the C allele
35Polymorphisms of the IL-6 Gene Promoter and AAAfollowing coronary artery surgery,20 the C allele was
associated with lower levels of CRP in our study.
This is not consistent with the association being on
the basis of inflammation. Furthermore, this variant
is too rare e seen in only 1.5% of cases e to be a useful
marker of AAA.
The grouped haplotype analysis identified IL-6
h.211 as a statistically significant risk factor for
AAA. From a functional perspective h211 may be as-
sociated with AAA because it is pro-inflammatory
and includes the -174G>C genotype which has
been shown to have an additive effect on peak IL-6
levels after coronary artery surgery.20 However, it
was the rarest (present in 4.4% of individuals) of the
four possible haplotypes examined and, as such, is
unlikely to be useful in understanding causation in
the majority of patients with AAAs. On balance, the
evidence from this and other genetic association stud-
ies raises the possibility that the inflammation seen in
AAAs could be secondary to the aneurysmal process
rather than causal.
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